Kawasaki disease, formerly known as the mucocutaneous lymph node syndrome, is a less commonly observed childhood disease that affects the blood vessels in children. This disease is a form of the condition known as vasculitis, which involves inflammation of the blood vessels. Kawasaki disease could lead to cardiovascular complications where it affects the coronary arteries carrying oxygenated blood to the heart. However, the frequency of cardiovascular complications has drastically reduced with the use of intravenous immune globulin (IVIG) therapy. The causes of Kawasaki disease are not well understood; however, it is assumed that the body’s response to different pathogenic microorganisms and viruses combined with genetic factors lead to the development of Kawasaki disease symptoms. Common symptoms of Kawasaki disease include fever which lasts for more than five days, red eyes & lips, and redness on the palms and feet soles. Various guidelines have been developed by the regulatory authorities for the treatment of the disease. Infusion of gamma globulins through intravenous route and dosage of aspirin are the most common therapeutic medications used to relieve the symptoms.
Kawasaki disease is becoming one of the most frequent causes of pediatric acquired heart disease in most of the developed countries such as the U.S., the U.K., Japan, Germany, and France. Prevalence of the disease is high in developing countries such as Brazil, China, India, and Russia. Moreover, this disease mostly affects boys than girls, and occurs in children aged between two years and five years. Rapid rise in incidence of Kawasaki disease in the emerging countries is likely to drive demand for therapeutic drugs during the forecast period. Increase in adoption of intravenous immunoglobulin therapy to prevent or reduce the coronary artery problems is projected to drive the Kawasaki disease therapeutics market during the forecast period. Furthermore, the underlining clinical trials using different drugs such as steroids and infliximab to treat the disease as the second line and tertiary treatment present significant opportunity in the near future.
The global Kawasaki disease therapeutics market can be segmented based on route of administration, distribution channel, and region. In terms of route of administration, the global market can be categorized into oral and intravenous. The intravenous segment is likely to dominate the global Kawasaki disease therapeutics market during the forecast period. The intravenous segment is projected to record high growth rate owing to increased adoption of this therapy for the prevention of cardiovascular complications. Based on distribution channel, the global Kawasaki disease therapeutics market can be segmented into hospital pharmacy, retail pharmacy, and e-commerce. The hospital pharmacy segment is anticipated to hold significant share by 2025. The retail pharmacy segment is projected to expand at the fastest growth rate during the forecast period.
Geographically, the global Kawasaki disease therapeutics market can be segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe are projected to account for high share of the global Kawasaki disease therapeutics market by 2025. According to the Kawasaki Disease Foundation, in the U.S. over 4,200 children are diagnosed with the disease each year. The market in Asia Pacific is projected witness exponential growth during the forecast period owing to increase in incidence of acquired heart disease caused due to Kawasaki disease. Japan is likely to dominate the market in the region during the forecast period.
Key players operating in the global Kawasaki disease therapeutics market include Shire plc, CSL Behring LLC, Grifols S.A., LFB Biomedicaments S.A., Kedrion S.p.A., Octapharma AG, Sanquin Plasma Products B.V., Bayer AG, and Novartis AG.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.